Retroperitoneal lymph node dissection for metastatic germ cell tumours
- PMID: 21944797
- PMCID: PMC3363081
- DOI: 10.1308/003588411X571098
Retroperitoneal lymph node dissection for metastatic germ cell tumours
Abstract
Introduction: In the North Trent Cancer network (NTCN) patients requiring retroperitoneal lymphadenectomy for metastatic testicular cancer have been treated by vascular service since 1990. This paper reviews our experience and considers the case for involvement of vascular surgeons in the management of these tumours.
Patients and methods: Patients referred by the NTCN to the vascular service for retroperitoneal lymphadenectomy between 1990 and 2009 were identified through a germ cell database. Data were supplemented by a review of case notes to record histology, intraoperative and postoperative details.
Results: A total of 64 patients were referred to the vascular service for retroperitoneal lymph node dissection, with a median age of 29 years (16-63 years) and a median follow-up of 4.9 years. Ten patients died: eight from tumour recurrence, one from septicaemia during chemotherapy and one by suicide. Of the 54 who survived, 7 were alive with residual masses and 47 patients were disease-free at the last follow-up. Sixteen patients required vascular procedures: four had aortic repair (fascia), three had aortic replacement (spiral graft), four had inferior vena cava resection, two had iliac artery replacement and two had iliac vein resection.
Conclusions: Retroperitoneal lymph node dissection often involves mobilisation and/or the resection/replacement of major vessels. We recommend that a vascular surgeon should be a part of testicular germ cell multidisciplinary team.
Figures


Similar articles
-
[Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].Urologe A. 2016 May;55(5):632-40. doi: 10.1007/s00120-016-0031-7. Urologe A. 2016. PMID: 26820659 German.
-
Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.BJU Int. 2010 Sep;106(6):779-85. doi: 10.1111/j.1464-410X.2009.09175.x. Epub 2010 Jan 19. BJU Int. 2010. PMID: 20089110
-
Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.Eur Urol. 2016 Oct;70(4):661-667. doi: 10.1016/j.eururo.2016.03.031. Epub 2016 Apr 5. Eur Urol. 2016. PMID: 27068395
-
Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.J Urol. 2021 Feb;205(2):370-382. doi: 10.1097/JU.0000000000001364. Epub 2020 Sep 11. J Urol. 2021. PMID: 32915080
-
[Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)].Urologia. 2010 Apr-May;77(2):84-7. Urologia. 2010. PMID: 20890864 Review. Italian.
References
-
- Manecksha RP, Fitzpatrick JM. Epidemiology of testicular cancer. BJU Int. 2009;104(9 Pt B):1,329–1,333. - PubMed
-
- Boyle P, Kaye SB, Robertson AG. Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol. 1987;23:827–830. - PubMed
-
- Doll R. Are we winning the war against cancer? A review in memory of Keith Durrant. Clin Oncol (R Coll Radiol) 1992;4:257–266. - PubMed
-
- Brown LM, Pottern LM, Hoover RN, et al. Testicular cancer in the United States: trends in incidence and mortality. Int J Epidemiol. 1986;15:164–170. - PubMed
-
- Stone JM, Cruickshank DG, Sandeman TF, Matthews JP. Trebling of the incidence of testicular cancer in Victoria, Australia (1950–1985) Cancer. 1991;68:211–219. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical